Clinically relevant drug interactions between anticancer drugs and psychotropic agents

Area of Science:

• Oncology
• Pharmacology
• Psychiatry

Background:

• Cancer patients frequently require psychotropic medications for psychological disorders, insomnia, or anxiety related to therapy.
• The concurrent use of anticancer drugs (ACDs) and psychotropics creates a high risk for drug-drug interactions (DDIs).

Purpose of the Study:

• To identify and characterize clinically significant drug-drug interactions between anticancer drugs and psychotropic medications.
• To provide clinicians with essential information for managing concurrent ACD and psychotropic therapy.

Main Methods:

• Compiled DDI data from authoritative drug information resources including the British National Formulary, Lexi-Comp, Micromedex, Hansten & Horn's Drug Interactions, and Drug Interaction Facts.
• Reviewed product information for individual drugs and relevant literature from PubMed and other databases focusing on ACD-psychotropic interactions.

Main Results:

• Identified pharmacokinetic DDIs involving tyrosine kinase inhibitors, corticosteroids, and antimicrotubule agents due to cytochrome P450 enzyme effects.
• Documented pharmacodynamic DDIs, including thalidomide with CNS depressants, procarbazine with antidepressants, myelosuppressive ACDs with clozapine, and anthracyclines with QT-prolonging psychotropics.

Conclusions:

• Clinicians must exercise vigilance when prescribing psychotropics concurrently with ACDs.
• Close monitoring of plasma drug levels is crucial to prevent toxicity and ensure therapeutic efficacy for both anticancer and psychotropic treatments.